Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study
Open Access
- 16 September 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 209 (5) , 658-667
Abstract
Background. Hepatitis C virus (HCV) entry involves scavenger receptor B1 (SRB1). In vitro, SRB1 inhibition by ITX5061 impedes HCV replication. Methods. Multicenter study to assess safety/activity of ITX5061 in previously untreated, noncirrhotic, HCV genotype 1 infected adults. Design included sequential cohorts of 10 subjects with ITX5061 (n = 8) or placebo (n = 2) to escalate duration (3 to 14 to 28 days) or deescalate dose (150 to 75 to 25 mg) based on predefined criteria for safety and activity (≥4 of 8 subjects with HCV RNA decline ≥1 log10 IU/mL). Results. Thirty subjects enrolled in 3 cohorts: ITX5061 150 mg/day by mouth for 3 (A150), 14 (B150), and 28 (C150) days. Six subjects had grade ≥3 adverse events (one in placebo); none were treatment related. One of the 7 C150 subjects (14.3%, 95% confidence interval [CI], .7%–55.4%) had ≥1 log10 IU/mL decline in HCV RNA (1.49 log10 IU/mL), whereas none of the 6 placebo, 8 A150 or 8 B150 subjects showed such decline. Conclusions. Oral ITX5061 150 mg/day for up to 28 days was safe and well tolerated. In the 28-day cohort, 1 of 7 subjects showed antiviral activity; however, predefined criteria for antiviral activity were not met at the doses and durations studied.Keywords
This publication has 23 references indexed in Scilit:
- Itx 5061 Quantitation in Human Plasma with Reverse Phase Liquid Chromatography and Mass Spectrometry DetectionAntiviral Therapy, 2013
- HCV’s days are numbered: next-generation direct-acting antivirals and host-targeting agentsAntiviral Therapy, 2012
- Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing AntibodiesJournal of Virology, 2008
- Claudin-1 is a hepatitis C virus co-receptor required for a late step in entryNature, 2007
- Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus andHostJournal of Virology, 2006
- Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger ReceptorJournal of Biological Chemistry, 2003
- Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BIProceedings of the National Academy of Sciences, 2002
- Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systemsJournal of Clinical Investigation, 2001
- Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective studyThe Lancet, 2001
- Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein ReceptorScience, 1996